Patents Examined by Ekaterina Poliakova-Georgantas
  • Patent number: 11097014
    Abstract: A nanoparticle delivery system designed for sustained delivery of microRNA-150 (miR-150) to FLT3-overexpressing acute myeloid leukemia (AML) cells, the delivery system comprising poly(amidoamine) (PAMAM) dendrimers complexed with miR-150, wherein at least one dendrimer is surface-functionalized with a ligand specific for FLT3 receptor, and methods for treating AML characterized by FLT3-overexpression are provided.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: August 24, 2021
    Assignees: University of Cincinnati, Board of Trustees of the University of Illinois, University of Chicago
    Inventors: Jianjun Chen, Seungpyo Hong, Xi Jiang, Zejuan Li
  • Patent number: 11091765
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a therapeutic target such as Complement Component 1, Q Subcomponent (C1q) or a subunit thereof.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: August 17, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Mark Miglarese, David Spetzler
  • Patent number: 11091759
    Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.
    Type: Grant
    Filed: December 7, 2016
    Date of Patent: August 17, 2021
    Assignee: Genzyme Corporation
    Inventors: Akin Akinc, Benny Sorensen, Pushkal Garg, Gabriel Robbie
  • Patent number: 11085045
    Abstract: The present invention provides functional aptamer-comprising tRNA molecules, useful in the study of tRNA and ribosomal activity.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: August 10, 2021
    Assignees: Anima Biotech Inc., Thomas Jefferson University
    Inventors: Iris Alroy, Ya-Ming Hou, Howard Gamper
  • Patent number: 11079379
    Abstract: Disclosed herein are methods for reducing or arresting an increase in a Neuropathy Impairment Score (NIS) or a modified NIS (mNIS+7) in a human subject by administering an effective amount of a transthyretin (TTR)-inhibiting composition.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: August 3, 2021
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventor: Brian Bettencourt
  • Patent number: 11072795
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 27, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Uttam Surana, Dave Keng Boon Wee, Jing Lin, Bing Lim
  • Patent number: 11066673
    Abstract: This invention relates to long non-coding RNAs (lncRNAs), libraries of those lncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting lncRNAs.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: July 20, 2021
    Assignee: The General Hospital Corporation
    Inventors: Jeannie T. Lee, Jing Zhao, Kavitha Sarma, Mark Borowsky, Toshiro Kendrick Ohsumi
  • Patent number: 11066672
    Abstract: This invention relates to compounds, compositions, and methods useful for reducing transth:yretin (TTR) target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: July 20, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventors: Bob D. Brown, Henryk T. Dudek
  • Patent number: 11058708
    Abstract: Galectin-3 is a pro-inflammatory molecule functioning as a cytokine hub, and also regulates unfolded protein responses (UPR) and ER stress. Thus, galectin-3 serves as a target for ameliorating inflammatory diseases such as allergic inflammation and diabetic inflammation and insulin resistance. RNA interference of endogenous galectin-3 expression, upregulates IL-12, IL-10 while downregulating IL-23 production, which offers protection against allergic inflammation. In addition, endogenous galectin-3 knockdown causes upregulation of XBP1, alleviating ER stress. Together, upregulated XBP1 and IL-10 offer protection against obesity-induced inflammation. Therefore, the embodiment of the invention resides in RNA interference of endogenous galectin-3 in appropriate cell types in order to rectify allergic and/or diabetic inflammation.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: July 13, 2021
    Inventor: Swey-Shen Chen
  • Patent number: 11046956
    Abstract: The present disclosure teaches the treatment of a blood pathology, such as a blood pathology associated with impaired hemoglobin synthesis including the treatment of ?-thalassemia or a related hemoglobinopathy.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 29, 2021
    Assignee: Hudson Institute of Medical Research
    Inventor: Jim Vadolas
  • Patent number: 11041153
    Abstract: Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide. Methods of treating patients with said delivery systems are also provided.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: June 22, 2021
    Assignee: BIO-PATH HOLDINGS, INC.
    Inventor: Ana Tari Ashizawa
  • Patent number: 11028393
    Abstract: The invention provides siRNA compositions that specifically downregulates expression of a variant of the PNPLA3 gene and methods of use thereof for treating a chronic liver disease or alcoholic liver disease (ALD).
    Type: Grant
    Filed: January 6, 2020
    Date of Patent: June 8, 2021
    Assignee: Purdue Research Foundation
    Inventors: Wanqing Liu, Yoon Yeo
  • Patent number: 11028395
    Abstract: The present invention relates to a TNF-?-binding RNA aptamer disclosed in SEQ ID NO: 1 or SEQ ID NO: 2, and to the therapeutic use thereof.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: June 8, 2021
    Assignee: BIOIS CO., LTD.
    Inventor: Sung-Chun Kim
  • Patent number: 11028391
    Abstract: Methods and compositions are provided for inhibiting or treating metastasis based on discoveries regarding Kif19 and Cep192. Methods and compositions are provided for enhancing wound healing, treating fibrosis, reducing scarring and treating nerve pain.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: June 8, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: David Sharp, Brian O'Rourke
  • Patent number: 11013755
    Abstract: The invention relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with bone loss, in particular osteoporosis and osteogenesis imperfect (01). The inhibitors are also useful for inducing an anabolic effect in bone, either alone or when administered in combination with parathyroid hormone or a recombinant fragment thereof. The invention further relates to inhibitors of microRNAs 19a and 19b and their use for treating or preventing conditions or diseases which are associated with reduced muscle function, in particular muscle degeneration and muscle atrophy. The inhibitors are also useful for stabilizing and/or strengthening muscle function. In addition, inhibitors of microRNAs 19a and 19b can be used for treating or preventing cancer-related bone destruction or bone metastasis.
    Type: Grant
    Filed: April 6, 2018
    Date of Patent: May 25, 2021
    Assignee: UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF
    Inventors: Eric Hesse, Hanna Taipaleenmäki, Hiroaki Saito
  • Patent number: 11015201
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the AGT gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an AGT gene and to methods of preventing and treating an AGT-associated disorder, e.g., high blood pressure.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: May 25, 2021
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Donald Foster, Gregory Hinkle, Mark K. Schlegel
  • Patent number: 11008571
    Abstract: Provided herein is a potent, optimized ?-catenin nucleic acid inhibitor molecule with a unique pattern of modified nucleotides. Also provided are methods and compositions for reducing ?-catenin expression and methods and compositions for treating cancer.
    Type: Grant
    Filed: October 17, 2018
    Date of Patent: May 18, 2021
    Assignee: Dicerna Pharmaceuticals, Inc.
    Inventor: Shanthi Ganesh
  • Patent number: 11001846
    Abstract: Aptamers, polynucleotides which participate in preventing the Porcine Respiratory and Reproductive Syndrome virus (PRRSV) infection of cells, and nucleic acid molecules, which include a polynucleotide sequence capable of specifically binding the polypeptides domain of the PRRSV that controls infection, constitute the core of the present invention. Also provided are methods of using such nucleic acid molecules, polynucleotides and synthetic antibodies directed against these, for detection, treating and neutralization of PRRSV infection.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: May 11, 2021
    Assignee: AEROVIRUS TECHNOLOGIES INC.
    Inventors: Norman Marchand, Thomas Caltagirone, Albert Liao
  • Patent number: 10941444
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules, such as lipoarabinomannan (LAM).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: March 9, 2021
    Assignee: Base Pair Biotechnologies, Inc.
    Inventors: George W. Jackson, Robert Batchelor, Rafal Drabek, Caitlin Bruns
  • Patent number: 10941176
    Abstract: Methods and compositions are provided for oligonucleotides that bind targets of interest. The targets include cells and microvesicles, such as those derived from various diseases. The oligonucleotides can be used for diagnostic and therapeutic purposes. The target of the oligonucleotides can be a target such as PARP1, HIST1H1B, HIST1H1D, NCL, FBL, SFPQ, RPL12, ACTB, HIST1H4A, SSBP1, NONO, H2AFJ, and DDX21, or a complex, subunit or fragment thereof.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: March 9, 2021
    Assignee: Caris Science, Inc.
    Inventors: Heather O'Neill, Günter Mayer, Mark Miglarese, David Spetzler